06/23/22 7:30 AMNasdaq : FSTX acquisitioninvoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical ProgramsProposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwide The transaction demonstrates the strength of F-star’s differentiated bispecific antibodyRHEA-AIpositive
05/10/22 8:00 AMNasdaq : FSTX earningsF-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateFour Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom andRHEA-AIneutral
05/02/22 9:00 AMNasdaq : FSTX F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that theRHEA-AIneutral
04/08/22 8:00 AMNasdaq : FSTX F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing nextRHEA-AIneutral
03/14/22 8:00 AMNasdaq : FSTX earningsF-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate UpdateMultiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 14, 2022 (GLOBERHEA-AIvery positive
03/10/22 8:00 AMNasdaq : FSTX conferencesF-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferenceF-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced thatRHEA-AIneutral
03/02/22 8:00 AMNasdaq : FSTX conferencesearningsF-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that theRHEA-AIneutral
03/01/22 8:00 AMNasdaq : FSTX managementF-star Therapeutics Appoints James Sandy as Chief Development OfficerF-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today thatRHEA-AIvery positive
01/20/22 8:00 AMNasdaq : FSTX F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stageRHEA-AIvery positive
01/07/22 8:00 AMNasdaq : FSTX conferencesF-star Therapeutics to Participate in Upcoming Investor ConferencesF-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today announcedRHEA-AIneutral